The third bellwether trial over blood thinner Xarelto began this week, but it’s missing one thing: Beth Wilkinson.

Wilkinson, of Washington, D.C.’s Wilkinson Walsh + Eskovitz, scored quick defense verdicts for Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. in the first two Xarelto trials earlier this year.